


Comprehensive Molecular Diagnostics for CML and MPN

Comprehensive CML and MPN molecular work-ups for a more informed patient status.


Quantitative BCR:ABL1 Panel:



ABL1 Resistance Panel:




Quantitative MPN Panel:




4 Breakpoint detection for broader coverage and **0.001% IS sensitivity** for superior diagnostics in initial work-ups and MRD monitoring.

For **BCR::ABL1 positive** patients, our ABL1 Resistance Panel detects ABL1 gene mutations associated with **therapy resistance** and **early relapse**.


For driver mutation status, including **co-expressions**, helping you make more informed treatment decisions that single gene reflex testing can miss.



3 Day TAT



7 Day TAT



CML/MPN Algorithm



BCR-ABL1, ABL1 Resistance, and MPN molecular panels have been validated as lab developed tests at Precipio. They have not been approved by the FDA.

For more information please contact:
contact@precipiodx.com | www.precipiodx.com | Tel: +1.203.787.7888

Efficient, Actionable Molecular Diagnostics for AML, CLL & Cytopenia

Cytopenia Panel:

Aid In CHIP & Early MDS Diagnosis/Prognosis From Peripheral Blood



Minimally invasive sampling to aid in the diagnosis and prognosis of **CHIP** and **early MDS**. **No bone marrow required.**



AML Panel:

Same-Day Panel Results to Guide Time-Sensitive Treatment Decisions

Therapeutic targets run in parallel for **rapid**, comprehensive molecular profiles that enable you to **determine the RIGHT treatment RIGHT away.**



CLL Panel:

Comprehensive Prognostic Insight

Prognostic panel to aid in patient treatment decisions from non-intervention to aggressive therapies.



Cytopenia, AML, and CLL molecular panels have been validated as lab developed tests at Precipio. They have not been approved by the FDA.

For more information please contact:

contact@precipiodx.com | www.precipiodx.com | Tel: +1.203.787.7888